Cumulative exposure to biologics and risk of cancer in psoriasis patients: A meta-analysis of Psonet studies from Israel, Italy, Spain, United Kingdom and Republic of Ireland.

CONCLUSION: Cumulative length of exposure to biologic therapies of psoriasis patients in real-world clinical practice does not appear to be linked to a higher risk of cancer after several years of use. This article is protected by copyright. All rights reserved. PMID: 29723914 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29723914?dopt=Abstract

Source: The British Journal of Dermatology - May 3, 2018 Category: Dermatology Authors: Garcia-Doval I, Descalzo MA, Mason KJ, Cohen AD, Ormerod AD, Gómez-García FJ, Cazzaniga S, Feldhamer I, Ali H, Herrera-Acosta E, Griffiths CEM, Stern R, Naldi L, Psonet Network Tags: Br J Dermatol Source Type: research